Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Eton Pharmaceuticals (NASDAQ:ETON) announced its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.12, Morningstar.com reports.

Eton Pharmaceuticals stock traded up $0.20 during mid-day trading on Wednesday, hitting $6.22. The company’s stock had a trading volume of 31,509 shares, compared to its average volume of 44,466. The stock’s 50 day moving average is $7.13. The firm has a market cap of $109.65 million and a P/E ratio of -1.07. The company has a current ratio of 5.89, a quick ratio of 5.89 and a debt-to-equity ratio of 0.01. Eton Pharmaceuticals has a 52-week low of $5.70 and a 52-week high of $10.20.

In other Eton Pharmaceuticals news, CEO Sean Brynjelsen acquired 10,000 shares of Eton Pharmaceuticals stock in a transaction that occurred on Tuesday, May 21st. The stock was purchased at an average cost of $7.93 per share, with a total value of $79,300.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 13.46% of the stock is currently owned by corporate insiders.

Several equities research analysts have recently commented on ETON shares. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Eton Pharmaceuticals in a report on Monday. ValuEngine raised Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Lake Street Capital assumed coverage on Eton Pharmaceuticals in a report on Monday. They set a “buy” rating for the company.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.

Read More: How a Put Option Works

Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit